A contrast in safety, pharmacokinetics, and pharmacodynamics across age groups after a single 50-mg oral dose of the gamma-secretase inhibitor avagacestat
Latest Information Update: 25 Jul 2012
At a glance
- Drugs Avagacestat (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 23 Jul 2012 New trial record